Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable polydl-lactide-co-glycolide microspheres (NET-90): Phase III clinical study

Advances in Contraception

Volumn 13, Issue 1, 1997, Pages 1-11

  Singh, M ^a   Saxena, B B ^a   Singh, R ^a   Kaplan, J ^a   Ledger, W J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; NORETHISTERONE; PROGESTERONE DERIVATIVE;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONGITUDINAL STUDY; MENSTRUATION DISORDER; MICROCAPSULE; PHASE 3 CLINICAL TRIAL; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; STANDARD; TIME; TREATMENT OUTCOME;

ADULT; CAPSULES; CONTRACEPTIVE AGENTS, FEMALE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MENSTRUATION DISTURBANCES; NORETHINDRONE; PREGNANCY; PROGESTERONE CONGENERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031089199     PISSN: 02674874     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006519027168     Document Type: Article

References (21)

1. Junkmann K, Witzel H. Chemie und Pharmakologie von Steroid-hormon-Estern. (Chemistry and pharmacology of steroidal hormone esters). Zeit Vit Hormone Fermentforsch. 1958;9:97-143.
2. Babcock JC, Outsell ES, Herr ME et al. 6-Methyl-17-hydroxyprogesterone 17-acylates: a new class of potent progestins. J Am Chem Soc. 1958;80(2):2904-5.
3. Upjohn Company. Depo-Provera for Contraception: Information for Public Board of Inquiry on Depo-Provera: Responses to the Board's Questions. Kalamazoo, MI: Upjohn, June 25. 1982:155.
4. Weisberg E. The Depo-Provera Controversy: Regulatory, Medical and Social Issues. In: Zambran D, ed. Depo-Provera (Medroxyprogesterone Acetate) for Contraception: A Current Prospective of Scientific, Clinical and Social Issues. Proceedings of an International Symposium held on 19-20 Nov, 1992, 2nd edn. Oxford: Oxford Clinical Communications. 1993:27-38.
5. Newton JR, Darcangues C, Hall PE. Once a month combined injectable contraceptives. J Obstet Gynecol. 1994;14(1):S1-34.
6. Stanford JL, Thomas DB. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. Int J Cancer. 1991;49:191-5.
7. Kew MC, Song E, Mohammed A, Hodkinson J. Contraceptive steroids as a risk for hepatocellular carcinoma: A case/control study in South African black women. Hepatology. 1990;227:298-302.
8. Oberle MW, Rosero-Bixby L, Irwin KL et al. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica. Int J Epidemiol. 1988;17(4):718-23.
9. Voight LF, Weiss NS. Epidemiology of endometrial cancer. Cancer Treat Res. 1989;49:1-21.
10. Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev. 1993;15(1):80-97.
11. Vessey MP. Benefits and risks of combined oral contraceptives. Meth Inform Med. 1993;32(3):222-4.
12. Robey B, Rutstein SO, Morris L, Blackburn R. The reproductive revolution: new survey findings. Population Reports, Series M, No.ll. Baltimore, Johns Hopkins School of Public Health, Population Information Program. 1992:44.
13. World Health Organization Task Force on Oral Contraceptives. A randomized, double-blind study of six oral contraceptives. Contraception. 1982;25(3):231-41.
14. Basnayake S. A study of 157 women who conceived after discontinuation of Depo Provera. (Colombia, Sri Lanka, Family Planning Association of Sri Lanka). 1981:9.
15. Pardthaisong T. Return of fertility after use of the injectable Depo-Provera: Up-dated data analysis. J Biosoc Sci. 1984;16(1):23-4.
16. Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception. 1974;10(2):181-202.
17. Warner-Rowe R. Personal communication. 1995.
18. World Health Organization. Injectable Contraceptives: Their Role in Family Planning Care. Geneva: WHO. 1990:117.
19. World Health Organization. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting. Bull World Health Organ. 1993;71(6):677-89.
20. Singh M, Saxena BB, Graver R, Ledger WJ. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-Iactide-co-glycolide microspheres: phase II clinical study. Fertil Steril. 1989;52(6):973-80.
21. Grubb GS, Welch JD, Cole L, Goldsmith A, Rivera R. A comparative evaluation of the safety and contraceptive effectiveness of 65 mg and 100 mg of 90-day norethindrone (NET injectable microspheres: a multicenter study). Fertil Steril. 1989;51(5):803-10.